BILLS-113hr2073ih.pdf

15 2010 20:11 May 24, 2013 VerDate Mar annually 2013 4 years 23:02 May 24 30, 2019 biennial 1ST SESSION H. R. 2073 MAY 21, 2013 each year 6 year 2.8 years months

the ‘‘Committee

PO 00000 Frm 00001 PO 00000 Frm 00002 PO 00000 Frm 00010 PO 00000 Frm 00007

New York Texas the United States of America

Committee Congress SEC Senate the Food and Drug Administration the House of Representatives ORDINATING COMMITTEE Food and Drug Administration tegic Health GENERAL.—The Committee Healthcare Research and Quality National Institutes non-Federal Health, Education Services Administration House of Representa- the Centers for Disease Control INTERAGENCY the Centers for Disease Control and Prevention the Committee on Energy the National Institutes of RESPONSIBILITIES.—In Ms. the Department of Health and Human Services NORTON ad- vance research Health and Human Services Commerce Agency the Committee on Energy and Commerce Labor

DSK3SPTVN1PROD VerDate Mar Pulmonary COSTA CAPPS BRADY BISHOP ROSKAM

pulmonary patients diagnosis heart lung recommendations accurate interagency blood early coordinating awareness options symptoms improve